Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024)

Lexaria Bioscience (LEXX) posted Current Deferred Revenue of $4963.0 for Q3 2024, up 16.09% sequentially from $4275.0 in Q1 2023.

Lexaria Bioscience (LEXX) Current Deferred Revenue (2016 - 2024) Analysis & Trends

Lexaria Bioscience has reported Current Deferred Revenue for 6 years, with the latest figure at $4963.0 in Q3 2024.

Quarterly Current Deferred Revenue changed N/A year-over-year to $4963.0 in Q3 2024, while the trailing twelve-month figure through Aug 2024 was $4963.0 (changed N/A YoY) and the FY2024 annual result came in at $4963.0, changed N/A from the prior year.
Current Deferred Revenue improved to $4963.0 in Q3 2024 per LEXX's latest filing, from $4275.0 in the prior quarter.
Over five years, Current Deferred Revenue peaked at $44255.0 in Q3 2020 and troughed at $1000.0 in Q1 2021.
A 4-year average of $16040.5 and a median of $5606.5 in 2020 frame the typical range for Current Deferred Revenue.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	139.13 Bn	131.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	85.77 Bn	77.77 Bn	3.93 Bn
3	Argenx Se	64.64 Bn	59.46 Bn	1.37 Bn
4	Moderna	58.29 Bn	53.16 Bn	52.00 Mn
5	BeOne Medicines	41.92 Bn	36.82 Bn	1.53 Bn
6	Alnylam Pharmaceuticals	31.58 Bn	28.28 Bn	992.69 Mn
7	BioNTech SE	28.12 Bn	9.73 Bn	668.28 Mn
8	Insmed	27.39 Bn	26.22 Bn	358.27 Mn
9	Royalty Pharma	27.27 Bn	26.43 Bn	-
10	Lexaria Bioscience	10.15 Mn	6.54 Mn	-

Download Data